Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer

NCT02092363 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

37

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: OMP-54F28, Paclitaxel and Carboplatin

Sponsor

OncoMed Pharmaceuticals, Inc.